Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ATERO: Tranexamic Acid for Epistaxis in Rendu-Osler Syndrome
NCT00355108Phase 3Completed
- Sponsor
- Hospices Civils de Lyon
- Start
- Sep 2006
- Primary completion
- May 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of tranexamic acid in hereditary hemorrhagic telangiectasia (HHT) (2 arms), sponsored by Hospices Civils de Lyon. Primary endpoint: Average monthly duration of epistaxis at 6 months. Started Sep 2006; status: completed.
02
Drugs
tranexamic acid
03
Conditions
hereditary hemorrhagic telangiectasia (HHT)
Beyond the preview
Go deeper on NCT00355108.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00355108.